• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diabetes Metab Res Rev . Hemoglobin A1C is a Predictor of COVID-19 Severity in Patients with Diabetes

tetano

Editor, Senior Moderator
Diabetes Metab Res Rev


. 2020 Aug 27;e3398.
doi: 10.1002/dmrr.3398. Online ahead of print.
Hemoglobin A1C is a Predictor of COVID-19 Severity in Patients with Diabetes


Eugene Merzon[SUP] 1 2 [/SUP], Ilan Green[SUP] 1 [/SUP], Miriam Shpigelman[SUP] 3 [/SUP], Shlomo Vinker[SUP] 1 2 [/SUP], Itamar Raz[SUP] 4 5 [/SUP], Avivit Golan-Cohen[SUP] 1 2 [/SUP], Roy Eldor[SUP] 6 7 [/SUP]



Affiliations

Abstract

Introduction: Poor outcomes of coronavirus disease 2019 (COVID-19) have been linked to diabetes but its relation to pre-infection glycemic control is still unclear.
Methods: To address this question we report here the association between pre-infection HemoglobinA1c (A1C) levels and COVID-19 severity as assessed by need for hospitalization in a cohort of 2068 patients with diabetes tested for COVID-19 in Leumit Health Services, Israel, between February 1 and April 30, 2020. Using the LHS integrated electronic medical records system we were able to collect a large amount of clinical information including age, sex, socioeconomic status, weight, height, body mass index, A1C, prior diagnosis of ischemic heart disease, depression/anxiety, schizophrenia, dementia, hypertension, cerebrovascular accident, congestive heart failure , smoking and chronic lung disease.
Results: Of the patients included in the cohort, 183 (8.85 %) were diagnosed with COVID-19 and 46 were admitted to hospital. More hospitalized patients were female, came from higher socioeconomic background and had a higher baseline A1C. A prior diagnosis of cerebrovascular accident and chronic lung disease conferred an increased risk of hospitalization but not obesity or smoking status. In a multivariate analysis, controlling for multiple prior clinical conditions, the only parameter associated with a significantly increased risk for hospitalization was A1C≥9%.
Conclusion: Using pre-infection glycemic control data we identify A1C as a clear predictor of COVID-19 severity. Pre-infection risk stratification is crucial to successfully manage this disease, efficiently allocate resources and minimize the economic and social burden associated with an undiscriminating approach. This article is protected by copyright. All rights reserved.

Keywords: Coronavirus infectious Disease 2019 (COVID-19); pre-infection glycemic control.
 
Back
Top Bottom